Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
RESEARCH TOOLSreports
Protagonist Therapeutics (PTGX) Ownership Overview
1.78% Insiders
16.13% Mutual Funds
0.17% Other Institutional Investors
28.66% ETFs
53.25% Public Companies and Individual Investors
The ownership structure of Protagonist Therapeutics (PTGX) stock is a mix of institutional, retail, and individual investors. Approximately 44.96% of the company’s stock is owned by Institutional Investors, 1.78% is owned by Insiders, and 53.25% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Feb 20, 2025 | Dinesh V Ph D Patel President & Ceo,director | xxxxxxxxxxxxx | $204607 |
| Nov 27, 2024 | Dinesh V Ph D Patel President & Ceo,director | xxxxxxxxxxxxx | $4680749 |
| Nov 27, 2024 | xxxxxxxxxxxxx | $1414402 | |
| Nov 27, 2024 | Suneel Gupta Cdo | xxxxxxxxxxxxx | $5635430 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2024 | xxxxxxxxxxxxx | $4053000 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $13112342 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $22477822 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $49086153 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 7,202,989 | Institution | 12.09% | 278,539,585 | |
| 5,930,006 | Institution | 9.95% | 229,313,332 | |
| 3,562,973 | Institution | 5.98% | 137,780,166 | |
| 2,750,750 | Institution | 4.62% | 106,371,503 | |
| 2,011,293 | Institution | 3.37% | 77,776,700 | |
| 1,714,062 | Institution | 2.88% | 66,282,778 | |
| 1,374,563 | Institution | 2.31% | 53,154,351 | |
| 990,988 | Institution | 1.66% | 38,321,506 | |
| 931,890 | Institution | 1.56% | 36,036,186 | |
| 736,992 | Institution | 1.24% | 28,499,481 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 2,750,750 | Institution | 4.62% | 106,371,503 | |
| 990,988 | Institution | 1.66% | 38,321,506 | |
| 639,518 | Institution | 1.07% | 24,730,161 | |
| 590,525 | Institution | 0.99% | 22,835,602 | |
| 425,342 | Institution | 0.71% | 16,447,975 | |
| 423,913 | Institution | 0.71% | 16,392,716 | |
| 413,026 | Institution | 0.69% | 15,971,715 | |
| 334,459 | Institution | 0.56% | 12,933,530 | |
| 289,342 | Institution | 0.49% | 11,188,855 | |
| 247,781 | Institution | 0.42% | 9,581,691 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 3,815,907 | Institution | 6.40% | 147,599,283 | |
| 1,857,777 | Institution | 3.12% | 71,710,192 | |
| 1,705,477 | Institution | 2.86% | 65,967,850 | |
| 1,566,802 | Institution | 2.63% | 60,588,233 | |
| 1,025,781 | Institution | 1.72% | 39,677,209 | |
| 894,662 | Institution | 1.50% | 34,533,953 | |
| 616,006 | Institution | 1.03% | 23,827,112 | |
| 550,886 | Institution | 0.92% | 21,302,762 | |
| 542,550 | Institution | 0.91% | 20,985,834 | |
| 519,593 | Institution | 0.87% | 20,092,661 |
FAQ
Who Owns Protagonist Therapeutics (PTGX)?
According to the latest TipRanks data, approximately 0.17% of the company's stock is held by institutional investors, 1.78% is held by insiders, and 53.25% is held by retail investors.
What percentage of Protagonist Therapeutics (PTGX) stock is held by institutional investors?
According to the latest TipRanks data, approximately 0.17% of Protagonist Therapeutics (PTGX) stock is held by institutional investors.
What percentage of Protagonist Therapeutics (PTGX) stock is held by retail investors?
According to the latest TipRanks data, approximately 53.25% of Protagonist Therapeutics (PTGX) stock is held by retail investors.
Who owns the most shares of Protagonist Therapeutics (PTGX)?
iShares owns the most shares of Protagonist Therapeutics (PTGX).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.